Therapeutic Efficacy and Safety of Fractional Carbon dioxide Laser versus Q-Switched Nd:YAG 1064 nm Laser in the treatment of Melasma- A Comparative Interventional Study
Keywords:
Melasma, MASI, fractional CO2 laser, Q-Switched ND:YAG 1064nm laserAbstract
Objective To compare the efficacy and safety profile of fractional CO2 laser versus Q-switched Nd:YAG 1,064 nm laser while treating various subtypes of melasma. Methods Eighty six patients of 18 years to 40 years of either gender, suffering from Melasma involving superficial epidermis, deep dermal melanosis or with coexisting both subtypes not taking any treatment for last 6 months were included. Patients with cutaneous and systemic co-morbidities were excluded. Pre-treatment MASI was calculated. Patients were randomized into two Groups, Group A and Group B with 43 patients each, with resistant melasma underwent Fractional Carbondioxide Laser and Q-Switched Nd:YAG 1064 nm Laser respectively. Treatment was done every four weeks for five consecutive sessions and response was assessed at one month follow up. Pictorial evidence of facial cutaneous melanosis was made into account using a DSLR camera at their first presentation to keep a record of primary lesion and prior to undergoing procedure (at four weeks interval) for comparison. Results Patients undergoing both the laser treatments mean age of 30.2±8.1 years. Fitzpatrick skin type V was most frequent followed by type IV. Majority (50.0%) had centrofacial melasma followed by malar (37.2%), mixed (9.3%) and mandibular (3.5%). It was epidermal in 52 (60.5%) patients while dermal and mixed in 14 (16.3%) and 20 (23.3%) patients respectively. A comparison between groups (A and B) was made on the basis of mean MASI score at presentation (16.4±12.9 vs. 16.8±18.6; p-value=0.921). Mean MASI score reduced significantly in both groups after 1 month of treatment; Group A (16.4±12.9 to 6.4±8.9; p-value<0.001) and Group B (16.8±18.6 to 12.3±15.2; p-value<0.001). The follow-up mean MASI score was markedly low in patients undergoing fractional CO2 laser in comparison with Q-switched Nd:YAG 1064 nm laser (6.4±8.9 vs. 12.3±15.2; p-value=0.030). Taking ≥60% reduction in baseline MASI score as efficacy, efficacy was significantly higher in cases with fractional CO2 laser treatment than Q-Switched Nd:YAG 1064 nm laser (86.0% vs.46.5%; p-value<0.001). Conclusion Fractional CO2 laser is more efficacious in treating melasma.References
Mehmood K, Nadeem M, Aman S, Hameed A, Kazmi AH. Role of progesterone and estrogen, prolactin in the etiopathogenesis of melasma in females. J Pak Assos Dermatol. 2011;21(4):241-7.
Tamega AD, Miot LD, Bonfietti C, Gige TC, Marques ME, Miot HA. Clinical patterns and epidemiological characteristics of facial melasma in Brazilian women. J Eur Acad Dermartol Venereol. 2013;27(2):151-6.
Miot LDB, Miot HA, Silva MG, Marques MEA. Fisiopatolagia do melasma. An Bras Dermatol. 2009;84:623-35.
Suh KS, Sung JY, Roh HJ, Jeon YS, Kim YC, Kim ST. Efficacy of the 1064-nm Q-switched Nd:YAG laser in melasma. J Dermatolog Treat. 2011;22(4):233-8.
Yaar M. Cutaneous pigmentation in health and disease: novel and well-established players. J Invest Dermatol. 2013;133:11–3.
Niloofar Y, Jalaly, Valizadeh N, Barikbin B, Yousefi M. Low-power fractional CO2 laser versus low-fluence Q-switch 1,064 nm Nd:YAG laser for treatment of melasma: A randomized, controlled, split-face study. Am J Clin Dermatol. 2014;15:357-63.
Neeley MR, Pearce FB, Collawn SS. Successful treatment of malar dermal melasma with a fractional ablative CO2 laser in a patient with type V skin. J Cosmet Laser Ther. 2010;12:258–60.
Sarkar R, Bansal S. Skin pigmentation in relation to gender: truth and myth. Pigment Int. 2017;4:1-2
Thingnes J, timothy J Lavelle et al. Understanding the melanocyte distribution in human epidermis:an agent based computational model approach. Plos One. 2012;7(7):e40377.
Brenner M, Vincent J. the protective role of melanin against UV damage in human skin. Photochem Photobiol. 2008;84(3):539-49.
Stacey A. N. D’Mello, Graeme J. Finlay,1 Bruce C. Baguley, Marjan E. Askarian-Amir. Signaling Pathways in Melanogenesis. Int J Mol Sci. 2016;17(7):1144.
Omi T, Numano K. The Role of the CO2 Laser and Fractional CO2 Laser in Dermatology. Laser Ther. 2014;23(1):49–60. Budamakuntla L, Loganathan E, Suresh DH, Shanmagun S. A randomized, open- label, comparative study of tranexamic acid microinjections and tranexamic acid with microneedling in patients with melasma. J Cutan Aesthet Surg. 2013;6:139-43.
Lima E. Microneedling in facial recalcitrant melasma: report of a series of 22 cases. An Bras Dermatol. 2015;90(6):919-21.
Ali R, Aman S, Nadeem M, Kazmi AH. Quality of life in patients of melasma. J Pak Assoc Dermatol. 2013;23(2):143-8.
Lee HS, Won CH, Lee DH. Treatment of melasma in asian skin using a fractional 1,550-nm laser: an open clinical study. Dermatol Surg. 2009;35:1499-1504.
Ejaz A, Raza N, Iftikhar N, Muzzafar F. Comparison of 30% salicylic acid with Jessner's solution for superficial chemical peeling in epidermal melasma. J Coll Physicians Surg Pak. 2008;18(4):205-8.
Aman S, Nadeem M, Mahmood K, Ghafoor MB. Pattern of skin diseases among patients attending a tertiary care hospital in Lahore, Pakistan. J Taibah Uni Med Sci. 2017;12(5):392-6.
Desale SP, Gugle AS, Kote R, Jadhav VM. Comparative study of efficacy of glycolic acid peel and intense pulsed light in the treatment of melasma. MVP J Med Sci. 2015;2(1):39-48.
Luqman N, Akhunzada WA, Luqman A, Khalid M, Jam S. Melasma; quality of life in patients. Professional Med J 2017; 24(12):1899-1903.
Divya KG, Narasimhan M, Rajagopalan V, Parveen B. Efficacy and safety of 70% glycolic acid versus q switched ND: YAG laser in the treatment of melasma: a comparative study. Int J Res Dermatol. 2017;3(1):1-6.
Kakru SN, Raihan M, Beg MA, Kakroo B. Efficacy of oral tranexamic acid in the treatment of melasma: a pilot study. Int Arch BioMed Clin Res. 2017;3(4):93-6.
Bari AU, Iqbal Z, Rahman SB. Tolerance and safety of superficial chemical peeling with salicylic acid in various facial dermatoses. Indian J Dermatol Venereol Leprol. 2005;71(2):87-90.
Sharma R, Mahajan VK, Mehta KS. Therapeutic efficacy and safety of oral tranexamic acid and that of tranexamic acid local infiltration with microinjections in patients with melasma: a comparative study. Clin Exp Dermatol. 2016;6(2):1-7.
Aamir S, Naseem R. Oral tranexamic acid in treatment of melasma in Pakistani population: a pilot study. J Pak Assoc Dermatol. 2014;24(3):198-203.
Aamir S, Rashid T, Nabi H, Haroon TS. Superficial chemical peeling with glycolic acid in melasma. J Pak Med Assoc. 2014;2(3):130-5.
